6C1 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces balance-sheet pressure and preserves financial flexibility while clinical programs advance. Improved equity and assets also indicate stronger capitalization than earlier periods, helping the company absorb operating volatility and fund development before requiring additional financing.
Probody PlatformA differentiated platform focused on conditional activation may support a broader pipeline of oncology candidates with the potential to improve treatment safety and therapeutic windows. That technology base can underpin proprietary programs and attract future collaboration or licensing opportunities.
High Gross ProfitabilityThe company’s collaboration and licensing model can generate very high gross profitability when revenue is recognized, preserving substantial contribution from upfront or milestone payments. If partnered programs achieve additional development or commercial events, this structure can provide economically attractive revenue.
Bears Say
Revenue ContractionSharp revenue declines and wide year-to-year swings show that current revenue is not stable or recurring. Dependence on collaboration, licensing, and milestone timing makes operating performance vulnerable to uneven program events, complicating planning and increasing the need for successful future partnerships.
Cash BurnSubstantial ongoing cash consumption means operations are not self-funding despite some improvement from prior annual burn levels. Continued negative operating cash flow increases reliance on existing reserves or external capital, potentially limiting development choices and creating financing pressure over the next several quarters.
Persistent LossesLarge losses and negative returns indicate that the company has not yet converted its platform and development activities into consistent profitability. This weak earnings base reduces internal funding capacity and leaves results dependent on future pipeline progress, partnerships, and milestone realization.
CytomX Therapeutics News
6C1 FAQ
What was CytomX Therapeutics Inc’s price range in the past 12 months?
Currently, no data Available
What is CytomX Therapeutics Inc’s market cap?
CytomX Therapeutics Inc’s market cap is CHF464.54M.
When is CytomX Therapeutics Inc’s upcoming earnings report date?
CytomX Therapeutics Inc’s upcoming earnings report date is Nov 10, 2026 which is in 29 days.
How were CytomX Therapeutics Inc’s earnings last quarter?
CytomX Therapeutics Inc released its earnings results on Aug 06, 2026. The company reported -CHF0.075 earnings per share for the quarter, missing the consensus estimate of -CHF0.064 by -CHF0.011.
Is CytomX Therapeutics Inc overvalued?
According to Wall Street analysts CytomX Therapeutics Inc’s price is currently Undervalued.
Does CytomX Therapeutics Inc pay dividends?
CytomX Therapeutics Inc does not currently pay dividends.
What is CytomX Therapeutics Inc’s EPS estimate?
CytomX Therapeutics Inc’s EPS estimate is -0.06.
How many shares outstanding does CytomX Therapeutics Inc have?
CytomX Therapeutics Inc has 217,899,280 shares outstanding.
What happened to CytomX Therapeutics Inc’s price movement after its last earnings report?
CytomX Therapeutics Inc reported an EPS of -CHF0.075 in its last earnings report, missing expectations of -CHF0.064. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of CytomX Therapeutics Inc?
Currently, no hedge funds are holding shares in CH:6C1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CytomX Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF11.00 (― Upside)
CHF11.00 (― Upside)
Blogger Sentiment
Bullish
CH:6C1 Sentiment 75%
Sector Average 67%
Sector Average 67%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.50%
12-Months-Change
Fundamentals
Return on Equity
-38.46%
Trailing 12-Months
Asset Growth
117.77%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CytomX Therapeutics Inc
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
6C1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical progress and clear near-term development and regulatory plans for Varseta-M (robust ORR 20%–32% and ~7 months PFS, completed optimization enrollment, combination and expansion strategies), backed by a materially strengthened balance sheet (cash up ~152.9%) and runway into H2 2028. Key risks remain operational and clinical: a large year-over-year revenue decline driven by completed collaborations, modest increases in operating costs, and the need to confirm that Grade 3 diarrhea can be reliably managed in the full optimization cohort and over longer follow-up. Overall, the positive clinical momentum and strong cash position outweigh the near-term financial and clinical uncertainties.View all CH:6C1 earnings summaries6C1 Stock 12 Month Forecast
Average Price Target
―Lexicon Pharmaceuticals
―
Verastem
―
Arcturus Therapeutics
―
―
Bicycle Therapeutics
―